Upcoming · By Invitation

International Translational Oncology Exchange

Boston · May 13, 202614:00 – 16:00 ET
Learn more →
←Back to Expert Scholars
research / researchcancer immunology

Caetano Reis e Sousa

卡埃塔诺·雷斯·索萨

DPhil

🏢The Francis Crick Institute(弗朗西斯·克里克研究所)🌐UK

Senior Group Leader, Immunobiology Laboratory免疫生物学实验室高级组长

85
h-index
2
Key Papers
4
Awards
3
Key Contributions

👥Biography 个人简介

Caetano Reis e Sousa is a world authority on type 1 conventional dendritic cells (cDC1) and cross-presentation. His group at the Francis Crick Institute has defined how cDC1s sense dying tumor cells through C-type lectin receptors and toll-like receptors, initiating CD8+ T cell anti-tumor immunity. He identified DNGR-1 (CLEC9A) as a key receptor for dead-cell sensing, fundamentally advancing cancer vaccine design.

Share:

🧪Research Fields 研究领域

cDC1 Dendritic CellscDC1树突细胞
Cross-Presentation交叉呈递
Pattern Recognition Receptors模式识别受体
Innate Immune Sensing先天免疫感知
Tumor Immunosurveillance肿瘤免疫监视

🎓Key Contributions 主要贡献

DNGR-1/CLEC9A Biology

Discovered DNGR-1 as a cDC1-specific receptor that recognizes actin exposed by dead tumor cells, enabling cross-presentation of tumor antigens to CD8+ T cells.

cDC1 in Anti-Tumor Immunity

Demonstrated that cDC1 cells are indispensable for spontaneous tumor rejection and response to checkpoint blockade immunotherapy.

Adjuvant Mechanisms

Elucidated how innate sensing pathways in DCs translate danger signals into T cell-activating adjuvant effects, informing rational vaccine adjuvant design.

Representative Works 代表性著作

[1]

DNGR-1 is a specific sensor of dying cells in the tumor microenvironment

Nature (2016)

Showed DNGR-1-expressing cDC1s capture dead tumor cell material to cross-prime CD8+ T cells, linking immunogenic cell death to adaptive anti-tumor responses.

[2]

Conventional type 1 dendritic cells focus on cross-presenting dead cell-associated antigens after sensing of CD8alpha+ tumor necrosis

Journal of Experimental Medicine (2020)

Defined the mechanistic link between tumor necrosis, DNGR-1 activation, and productive anti-tumor CD8+ T cell priming in vivo.

🏆Awards & Recognition 奖项与荣誉

🏆FRS Fellow of the Royal Society
🏆EMBO Member
🏆William B. Coley Award for Distinguished Research in Basic and Tumor Immunology
🏆European Research Council Advanced Grant

📄Data Sources 数据来源

Institution

Last updated: 2026-01-15 | All information from publicly available academic sources

Related Experts 相关专家

Faisal Mahmood

Brigham and Women's Hospital; Harvard Medical School

Computational Pathology — Deep Learning for Whole-Slide Image Analysis and Tumor Microenvironment CharacterizationFoundation Models for Pathology — CONCH and TITAN Vision-Language Models for Oncology

Kun-Hsing Yu

Harvard Medical School; Brigham and Women's Hospital

Multimodal Oncology AI — Integrating Pathology Images, Genomics, Proteomics, and Clinical RecordsAI Pathology-Genomics Integration — Predicting Molecular Alterations from Histomorphology

Ziad Obermeyer

University of California, Berkeley; UC San Francisco

Algorithmic Bias in Healthcare AI — Racial Disparities in Predictive Risk ScoresPredictive Models for Cancer and Critical Illness — Machine Learning in Clinical Practice

Andrew H. Beck

PathAI; Harvard Medical School (formerly)

PathAI — Founding and Scientific Direction of AI-Powered Pathology PlatformDeep Learning for Pathology Biomarker Discovery — TILs, Fibrosis, and Tumor Architecture

关注 卡埃塔诺·雷斯·索萨 的研究动态

Follow Caetano Reis e Sousa's research updates

留下邮箱，当我们发布与 Caetano Reis e Sousa（The Francis Crick Institute）相关的新研究或访谈时，我们会通知你。

我们不会泄露你的信息，也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment

Browse All ExpertsRead Research Insights